H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Ritter Pharmaceuticals (NASDAQ: RTTR) today and set a price target of $15. The company’s shares closed yesterday at $3.43.
Selvaraju observed:
“Week. We draw investors’ attention to the fact that Ritter Pharmaceuticals presented two posters on its RP-G28 lead clinical program at the Digestive Disease Week (DDW) medical meeting this week. DDW is one of the premier conferences in the gastroenterology sector and we believe these poster presentations effectively delineate key elements of the RP- G28 clinical program. The first poster highlights RP-G28’s treatment benefit in safely and effectively reducing or eliminating key symptoms of lactose intolerance (LI), while the second outlines the development and validation of a novel tool to measure changes in the severity of LI symptoms over time and shows the instrument’s reliability and responsiveness, illustrating its utility for evaluating treatment intervention effects.”
According to TipRanks.com, Selvaraju is a 2-star analyst with an average return of 0.8% and a 41.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Ritter Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $15.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.98 and a one-year low of $1.83. Currently, Ritter Pharmaceuticals has an average volume of 340.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ritter Pharmaceuticals, Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat gastrointestinal diseases. It focuses on the development and commercialization of RP-G28. The company was founded by Andrew J. Ritter and Ira E. Ritter on March 29, 2004 and is headquartered in Los Angeles, CA.
